AU2021281426A1 - Methods for the treatment of infantile spasms using medium chain triglycerides - Google Patents

Methods for the treatment of infantile spasms using medium chain triglycerides Download PDF

Info

Publication number
AU2021281426A1
AU2021281426A1 AU2021281426A AU2021281426A AU2021281426A1 AU 2021281426 A1 AU2021281426 A1 AU 2021281426A1 AU 2021281426 A AU2021281426 A AU 2021281426A AU 2021281426 A AU2021281426 A AU 2021281426A AU 2021281426 A1 AU2021281426 A1 AU 2021281426A1
Authority
AU
Australia
Prior art keywords
spasms
composition
subject
day
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021281426A
Other languages
English (en)
Inventor
Samuel T. Henderson
Judith WALKER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cerecin Inc
Original Assignee
Cerecin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerecin Inc filed Critical Cerecin Inc
Publication of AU2021281426A1 publication Critical patent/AU2021281426A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • External Artificial Organs (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021281426A 2020-05-29 2021-05-28 Methods for the treatment of infantile spasms using medium chain triglycerides Pending AU2021281426A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063032111P 2020-05-29 2020-05-29
US63/032,111 2020-05-29
US202163176747P 2021-04-19 2021-04-19
US63/176,747 2021-04-19
PCT/US2021/034883 WO2021243226A1 (en) 2020-05-29 2021-05-28 Methods for the treatment of infantile spasms using medium chain triglycerides

Publications (1)

Publication Number Publication Date
AU2021281426A1 true AU2021281426A1 (en) 2023-02-02

Family

ID=78744111

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021281426A Pending AU2021281426A1 (en) 2020-05-29 2021-05-28 Methods for the treatment of infantile spasms using medium chain triglycerides

Country Status (8)

Country Link
US (1) US20230181512A1 (https=)
EP (1) EP4157250A4 (https=)
JP (1) JP2023527454A (https=)
KR (1) KR20230018462A (https=)
CN (1) CN115884766A (https=)
AU (1) AU2021281426A1 (https=)
CA (1) CA3184353A1 (https=)
WO (1) WO2021243226A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3595638A4 (en) * 2017-03-15 2020-09-16 Cerecin Inc. PHARMACEUTICAL COMPOSITIONS WITH HIGH DRUG LOADS BASED ON MEDIUM-CHAIN TRIGLYCERIDES AND RELATED METHODS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL164089A0 (en) * 2002-04-30 2005-12-18 Suntory Ltd Astaxanthin medium-chain fatty acidester, production method of the same, and composition comprising the same
KR20070034591A (ko) * 2004-06-17 2007-03-28 위스콘신 얼럼나이 리서어치 화운데이션 발작 및 발작병을 치료하기 위한 화합물 및 방법
CA2882708A1 (en) * 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
US11331279B2 (en) * 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
CA2986268C (en) * 2015-05-28 2024-01-02 Insys Development Company, Inc. Stable cannabinoid formulations
EP3462885A4 (en) * 2016-05-27 2020-01-22 Insys Development Company, Inc. STABLE CANNABINOID FORMULATIONS
EP3481387A4 (en) * 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
AU2017347778A1 (en) * 2016-10-24 2019-05-16 University Of South Florida Delaying latency to seizure by combinations of ketone supplements
CN110678173B (zh) * 2017-04-10 2023-03-28 维塔弗洛国际有限公司 用于治疗癫痫的组合物
US10682317B2 (en) * 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation

Also Published As

Publication number Publication date
CN115884766A (zh) 2023-03-31
US20230181512A1 (en) 2023-06-15
CA3184353A1 (en) 2021-12-02
WO2021243226A1 (en) 2021-12-02
EP4157250A1 (en) 2023-04-05
JP2023527454A (ja) 2023-06-28
EP4157250A4 (en) 2024-06-19
KR20230018462A (ko) 2023-02-07

Similar Documents

Publication Publication Date Title
US8748400B2 (en) Use of ketogenic compounds for treatment of age-associated memory impairment
US20100261791A1 (en) Compositions and Methods for Improving or Preserving Brain Function
US10111849B2 (en) Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US20070135376A1 (en) Method to reduce oxidative damage and improve mitochondrial efficiency
JP5674652B2 (ja) 神経障害の処置のためのアセトアセテートのモノグリセリドおよび誘導体
US20230181512A1 (en) Methods for the treatment of infantile spasms using medium chain triglycerides
WO2023212326A1 (en) Administration of r-beta-hydroxybutyrate and related compounds in veterinary applications
Herrero et al. Ketogenic dietary therapies for epilepsy: Experience in 160 patients over 18 years
JP2024532156A (ja) トリカプリリンを使用する片頭痛および関連頭痛症状の処置のための方法